Please login to the form below

Not currently logged in
Email:
Password:

Dr Antoine Yver moves from AstraZeneca to Daiichi Sankyo

He becomes global head, oncology research and development

Daiichi Sankyo Dr Antoine YverDaiichi Sankyo has appointed Dr Antoine Yver to the newly-created position of global head, oncology research and development.

Reporting directly to Dr Glenn Gormley, Daiichi Sankyo's president and global head of research and development, Dr Yver will oversee the entirety of the firm's global research and development in the oncology therapeutic area.

Dr Gormley said: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.

“We are confident that Antoine will provide great leadership and strategic insights in this new role, which underscores Daiichi Sankyo's commitment to the fight against cancer.”

Dr Yver moves from AstraZeneca, where he has served as senior vice president and head of oncology global medicines development as well as leading its global medicines development in China since 2012.

Prior to this, he has held senior management roles in oncology research at Aventis, Johnson & Johnson and Schering-Plough.

Dr Yver said: “I'm excited to join such a respected company and further build its presence in this important field.

“I have been most impressed by the quality of science at Daiichi Sankyo and the company's strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”

6th April 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics